9-(4-hydroxybutyl)-N2-phenylguanine
Star0
Identification
- Generic Name
- 9-(4-hydroxybutyl)-N2-phenylguanine
- DrugBank Accession Number
- DB02495
- Background
9-(4-hydroxybutyl)-N2-phenylguanine is a solid. This compound belongs to the hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. 9-(4-hydroxybutyl)-n2-phenylguanine is known to target thymidine kinase.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 299.3278
Monoisotopic: 299.138224813 - Chemical Formula
- C15H17N5O2
- Synonyms
- HBPG
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UThymidine kinase inhibitorHHV-1 - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Imidazopyrimidines
- Sub Class
- Purines and purine derivatives
- Direct Parent
- Hypoxanthines
- Alternative Parents
- 6-oxopurines / Aniline and substituted anilines / Pyrimidones / Aminopyrimidines and derivatives / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Secondary amines / Azacyclic compounds / Alkanolamines show 4 more
- Substituents
- 6-oxopurine / Alcohol / Alkanolamine / Amine / Aminopyrimidine / Aniline or substituted anilines / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- JHBXNPBKSPYOFT-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H17N5O2/c21-9-5-4-8-20-10-16-12-13(20)18-15(19-14(12)22)17-11-6-2-1-3-7-11/h1-3,6-7,10,21H,4-5,8-9H2,(H2,17,18,19,22)
- IUPAC Name
- 9-(4-hydroxybutyl)-2-(phenylamino)-6,9-dihydro-1H-purin-6-one
- SMILES
- OCCCCN1C=NC2=C1N=C(NC1=CC=CC=C1)NC2=O
References
- General References
- Kaufman HE, Varnell ED, Wright GE, Xu H, Gebhardt BM, Thompson HW: Effect of 9-(4-hydroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, on clinical recurrences of ocular herpetic keratitis in squirrel monkeys. Antiviral Res. 1996 Dec;33(1):65-72. [Article]
- Gebhardt BM, Focher F, Eberle R, Manikowski A, Wright GE: Effect of combinations of antiviral drugs on herpes simplex encephalitis. Drug Des Devel Ther. 2009 Dec 29;3:289-94. [Article]
- External Links
- PDB Entries
- 1qhi
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.775 mg/mL ALOGPS logP 1.44 ALOGPS logP 1.15 Chemaxon logS -2.6 ALOGPS pKa (Strongest Acidic) 9.43 Chemaxon pKa (Strongest Basic) 0.48 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 91.54 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 85.06 m3·mol-1 Chemaxon Polarizability 31.23 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9928 Blood Brain Barrier + 0.9145 Caco-2 permeable - 0.8142 P-glycoprotein substrate Substrate 0.6717 P-glycoprotein inhibitor I Non-inhibitor 0.7652 P-glycoprotein inhibitor II Non-inhibitor 0.7262 Renal organic cation transporter Non-inhibitor 0.5997 CYP450 2C9 substrate Non-substrate 0.748 CYP450 2D6 substrate Non-substrate 0.7243 CYP450 3A4 substrate Non-substrate 0.5204 CYP450 1A2 substrate Non-inhibitor 0.6718 CYP450 2C9 inhibitor Non-inhibitor 0.7567 CYP450 2D6 inhibitor Non-inhibitor 0.9194 CYP450 2C19 inhibitor Non-inhibitor 0.8972 CYP450 3A4 inhibitor Non-inhibitor 0.9169 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7985 Ames test Non AMES toxic 0.5413 Carcinogenicity Non-carcinogens 0.9133 Biodegradation Not ready biodegradable 0.9389 Rat acute toxicity 2.1388 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.746 hERG inhibition (predictor II) Non-inhibitor 0.6504
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0udi-0009000000-daf0a3100ef284259045 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0090000000-592889295476f262bcb5 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0059-0090000000-004bdbbd3a357c895ac3 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0059-0390000000-66195bb441b4f9b61fe5 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-1191000000-32c9d13a2ed064da43b7 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-05mw-1920000000-e41349e156cf2d9c3a18 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 186.0849893 predictedDarkChem Lite v0.1.0 [M-H]- 160.25926 predictedDeepCCS 1.0 (2019) [M+H]+ 187.7510893 predictedDarkChem Lite v0.1.0 [M+H]+ 162.61726 predictedDeepCCS 1.0 (2019) [M+Na]+ 186.3795893 predictedDarkChem Lite v0.1.0 [M+Na]+ 168.71043 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsThymidine kinase
- Kind
- Protein
- Organism
- HHV-1
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Thymidine kinase activity
- Specific Function
- In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate the...
- Gene Name
- TK
- Uniprot ID
- Q9QNF7
- Uniprot Name
- Thymidine kinase
- Molecular Weight
- 40896.475 Da
References
- Gebhardt BM, Wright GE, Xu H, Focher F, Spadari S, Kaufman HE: 9-(4-Hydroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, suppresses herpes virus reactivation in mice. Antiviral Res. 1996 May;30(2-3):87-94. doi: 10.1016/0166-3542(95)00900-0. [Article]
Drug created at June 13, 2005 13:24 / Updated at April 30, 2023 10:33